Trastuzumab regimens for HER2-overexpressing metastatic breast cancer

Clinical Breast Cancer

Volumn 4, Issue 5, 2003, Pages 329-337

  Spigel, David R ^a   Burstein, Harold J ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Advanced breast cancer; Chemotherapy; Combination therapy; Flourescence in situ hybridization; Immunohistochemistry

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; LIPOSOME; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB;

AREA UNDER THE CURVE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOMYOPATHY; CHILL; CLINICAL STUDY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; GENE OVEREXPRESSION; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; LACRIMATION; LEUKOPENIA; METASTASIS; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROPATHY; NEUROTOXICITY; PAIN; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; STANDARD; THROMBOCYTOPENIA; VOMITING;

EID: 0942266277     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.n.038     Document Type: Review

References (48)

1. US Food and Drug Administration. Product Approval Information-Licensing Action. Rockville, MD: FDA, 2001.
2. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
3. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
4. Franco S, Vogel C. The Fornier Article Reviewed [commentary]. Oncology 2003; 16:1356-1358.
5. Wong ZW, Isaacs C, Harris L, et al. A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer. Presented at: 26th Annual San Antonio Breast Cancer Symposium; December 3-6, 2003; San Antonio, TX. Abstract #444.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
7. Osoba D, Slamon DJ, Burchmore M, et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20:3106-3113.
8. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-2251.
9. Konecny G, Pegram M, Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin against breast cancer cell lines with HER-2/neu overexpression. Breast Cancer Res Treat 1999; 57(suppl):S114 (Abstract #467).
10. Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16:2659-2671.
11. Sledge GW Jr, Loehrer PJ Sr, Roth BJ, et al. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988; 6:1811-1814.
12. Seidman AD, Fornier MN, Esteva FJ, et al, Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19:2587-2595.
13. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13:2886-2894.
14. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17:2341-2354.
15. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:1800-1808.
16. Montemurro F, Choa G, Faggiuolo R, et al. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. Am J Clin Oncol 2003; 26:95-97.
17. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19:2722-2730.
18. Papaldo P, Fabi A, Pino M, et al. Comparison between vinorelbine in HER2-negative and vinorelbine plus trastuzumab in HER2-positive pretreated metastatic breast cancer patients. Proc Am Soc Clin Oncol 2003; 22:74 (Abstract #296).
19. Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 2002; 7:410-417.
20. Chan A, Untch M, Petruzelka L, et al. Multinational phase II study of navelbine and herceptin as first-line therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2002; 76(suppl):S112 (Abstract #434).
21. O'Shaughnessy J, Vukelja SJ, Marsland T, et al. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin Breast Cancer 2002; 3(suppl 1):S17-S20.
22. Hirsch FR, Helfrich B, Franklin WA, et al. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. Clin Breast Cancer 2002; 3(suppl 1):S12-S16.
23. Christodoulou C, Fountzilas G, Razi E, et al. Gemcitabine and trastuzumab combination as salvage treatment in patients with HER 2-positive metastatic breast cancer. Proc Am Soc Clin Oncol 2003; 22:42 (Abstract #166).
24. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002; 49:211-216.
25. Burstein HJ, Harris LN, Marcom PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003; 21:2889-2895.
26. Loesch D, Robert N, Asmar L, et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol 2002; 20:3857-3864.
27. Robert N, Leyland-Jones B, Asmar L, et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002; 76(suppl):S37 (Abstract #35).
28. Robert N. Beyond the standard: new combinations for the management of Her2-positive metastatic breast cancer. Biologic Therapies: Innovative Strategies for Managing Breast Cancer Houston: US Oncology Research Network, 2003:1-2.
29. Yardley D, Greco F, Hainsworth J, et al. Final results of the Minnie Pearl Cancer Research Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab in metastatic breast cancer. Breast Cancer Res Treat 2002; 76(suppl):S113 (Abstract #439).
30. Rowland K, Suman V, Ingle J, et al. NCCTG 98-32-52: Randomized phase II trial of weekly versus every 3-week administration of paclitaxel, carboplatin and trastuzumab in women with HER2 positive metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003; 22:8 (Abstract #31).
31. Nabholtz J, Pienkowski T, Northfelt D, et al. Results of two open label multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts cis or carboplatin (TCH) as therapy for advanced breast cancer in women with tumors over-expressing the HER2-neu protooncogene. Eur J Cancer 2001; 37(suppl 6):S190.
32. Brufsky A, Cleary D, Fuchs C, et al. First-line chemotherapy for metastatic breast cancer (MBC) with docetaxel (T), carboplatin (C), and trastuzumab (H) (TCH): a phase II trial. Proc Am Soc Clin Oncol 2003; 22:18 (Abstract #71).
33. Miller K, Sisk J, Gize G, et al. Phase II study of gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer: a Hoosier Oncology Group trial. Breast Cancer Res Treat 2002; 76(suppl):S116 (Abstract #437).
34. Sledge GW Jr. Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer. Semin Oncol 2003; 30:19-21.
35. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21:588-592.
36. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20:3095-3105.
37. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002; 94:855-857.
38. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002; 94:852-854.
39. Gelmon K, Arnold A, Verma S, et al. Pharmacokinetics and safety of trastuzumab when administered every three weeks to women with metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20:69a (Abstract #271).
40. Tripathy D, Slamon D, Leyland-Jones B, et al. Treatment beyond progression in the Herceptin pivotal combination chemotherapy trial. Breast Cancer Res Treat 2000; 64(suppl):S32 (Abstract #25).
41. Gelmon K, Mackey J, Verma S, et al. Efficacy and safety of Herceptin in women with HER2-positive metastatic breast cancer who have progressed on a prior Herceptin-containing regimen. Breast Cancer Res Treat 2002; 76(suppl):S113 (Abstract #440).
42. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. Clin Breast Cancer 2003; 4:120-125.
43. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215-1221.
44. Dieras V, Fumoleau P, Lotz J, et al. Previous cumulative dose is the main determinant of IVEF decrease in breast cancer patients treated with trastuzumab: results of a French compassionate use program. Breast Cancer Res Treat 2002; 76(suppl):S110 (Abstract #425).
45. Lunardi G, Vannozzi MO, Bighin C, et al. Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. Ann Oncol 2003; 14:1222-1226.
46. Venturini M, Nicoletto O, Bighin C, et al. A multicenter phase II study of trastuzumab with epirubicin and docetaxel as a first line treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 2003; 22:34 (Abstract #134).
47. Wolff A, Bonetti M, Sparano J, et al. Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): Preliminary results of the Eastern Cooperative Oncology Group trial E3198. Proc Am Soc Clin Oncol 2003; 22:18 (Abstract #70).
48. Theodoulou M, Campos S, Welles L, et al. Preliminary cardiac safety and efficacy data from a phase I/II trial of TLC D-99 (D-99) and trastuzumab (T) in patients (PTS) with locally advanced or metastatic breast cancer (LABC/MBC). Proc Am Soc Clin Oncol 2001; 20:46a (Abstract #180).